The Patent Trial and Appeal Board was initially created to provide a faster, cheaper solution for patent disputes, but has been exploited by Big Tech firms to drain the resources of smaller rivals.
The bipartisan PREVAIL Act aims to curb abusive patent challenges by banning duplicative litigation, ensuring that smaller companies can defend their intellectual property without facing overwhelming legal battles.
Critics of the PREVAIL Act argue it may lead to higher drug prices, but this concern appears to be a disguise for Big Tech’s opposition to preventing them from devaluing patented innovations.
The lobbying efforts by Big Tech firms against the PREVAIL Act reveal a lack of a legitimate defense for their practices, as the argument boils down to maintaining the status quo of intellectual property theft.
Collection
[
|
...
]